Why Eli Lilly's Immunology Prospects Look Promising
Top pharmaceutical company Eli Lilly's (NYSE: LLY) diabetes division achieved a key milestone with the approval of Mounjaro in May for type 2 diabetes. But not to be outdone, the company's immunology division has responded with a string of good news.
This is a turnaround from earlier this year when the prospects of key immunology blockbuster Olumiant were dampened by Food and Drug Administration (FDA) concerns over its safety. Lilly's strengthening outlook for its immunology treatments has the potential to shore up future revenue growth.
Image source: Getty Images.
Source Fool.com
